Skip to content

A Clinical Study to compare the Efficacy and Safety of Marham-e-DÄ?d with Terbinafine in the Management of QÅ«bÄ? (Ringworm)

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to compare the Efficacy and Safety of Marham-e-DÄ?d with Terbinafine in the Management of QÅ«bÄ? (Ringworm)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/051134
Enrollment
60
Registered
2023-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Marham-e- DÄ?d: sufficient quantity of Cream will be mix with vinegar and apply locally on affected part twice daily for 42 days Control Intervention1: Terbinafine cream 1%: sufficient

Sponsors

National Research Institute of Unani Medicine for Skin Disorders
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) 1. Circumscribed lesions having any of the following signs and symptoms on body: .Presence of pruritus and burning .Presence of scales_ .Presence of central clearing .Erythematous papules b) Participants with positive mycology (KOH positive). c)| Participants of either sex in age group of 19-60 years.

Exclusion criteria

Exclusion criteria: a) Co-morbid conditions of the participants b) Pregnant or Lactating Women c) Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction d) Known cases of Immuno-compromised states (HIV/ AIDS, etc.)/Malignancies Participants not willing to attend treatment schedule regularly e) History of hypersensitivity to Itraconazole and Terbinafine. F) Patient having diabetic. g) Participants using the following medications: . Systemic antifungal within 15 days of baseline visit. . Systemic corticosteroids within 15 days of baseline visit.

Design outcomes

Primary

MeasureTime frame
Total Signs and Symptoms Score(TSSS) Timepoint: 42 days

Secondary

MeasureTime frame
1.Conversion to Negative Mycology 2.Systemic Safety AssesssmentTimepoint: 42 days

Countries

India

Contacts

Public ContactAnam Farah Sayyed Nisar

National Research Institute of Unani Medicine for Skin Disorders

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026